Guided Therapeutics, Inc. (GTHP)
- Previous Close
0.0850 - Open
0.0641 - Bid --
- Ask --
- Day's Range
0.0641 - 0.1045 - 52 Week Range
0.0620 - 0.3000 - Volume
59,344 - Avg. Volume
25,572 - Market Cap (intraday)
5.45M - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0700 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Guided Therapeutics, Inc., a medical technology company, develops medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is headquartered in Peachtree Corners, Georgia.
www.guidedinc.comRecent News: GTHP
Performance Overview: GTHP
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GTHP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GTHP
Valuation Measures
Market Cap
4.73M
Enterprise Value
9.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
44.35
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-85.82%
Return on Equity (ttm)
--
Revenue (ttm)
98k
Net Income Avi to Common (ttm)
-3.76M
Diluted EPS (ttm)
-0.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
591k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-988.38k
Research Analysis: GTHP
Company Insights: GTHP
GTHP does not have Company Insights